FDA grants Roche's Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer

Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early-stage breast cancer.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news